FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging

Janina Krell-Roesch, Hanna Ruider, Val Lowe, Gorazd B. Stokin, Anna Pink, Rosebud O Roberts, Michelle M Mielke, David S Knopman, Teresa J. Christianson, Mary Margaret Machulda, Clifford R Jr. Jack, Ronald Carl Petersen, Yonas Endale Geda

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

One of the key research agenda of the field of aging is investigation of presymptomatic Alzheimer's disease (AD). Furthermore, abnormalities in brain glucose metabolism (as measured by FDG-PET) have been reported among cognitively normal elderly persons. However, little is known about the association of FDG-PET abnormalities with neuropsychiatric symptoms (NPS) in a population-based setting. Thus, we conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging in order to examine the association between brain glucose metabolism and NPS among cognitively normal (CN) persons aged>70 years. Participants underwent FDG-PET and completed the Neuropsychiatric Inventory Questionnaire (NPI-Q), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Cognitive classification was made by an expert consensus panel. We conducted multivariable logistic regression analyses to compute odds ratios (OR) and 95 confidence intervals after adjusting for age, sex, and education. For continuous variables, we used linear regression and Spearman rank-order correlations. Of 668 CN participants (median 78.1 years, 55.4 males), 205 had an abnormal FDG-PET (i.e., standardized uptake value ratio<1.32 in AD-related regions). Abnormal FDG-PET was associated with depression as measured by NPI-Q (OR=2.12; 1.233.64); the point estimate was further elevated for APOE ϵ4 carriers (OR=2.59; 1.006.69), though marginally significant. Additionally, we observed a significant association between abnormal FDG-PET and depressive and anxiety symptoms when treated as continuous measures. These findings indicate that NPS, even in community-based samples, can be an important additional tool to the biomarker-based investigation of presymptomatic AD.

Original languageEnglish (US)
Pages (from-to)1609-1616
Number of pages8
JournalJournal of Alzheimer's Disease
Volume53
Issue number4
DOIs
StatePublished - 2016

Fingerprint

Asymptomatic Diseases
Equipment and Supplies
Alzheimer Disease
Odds Ratio
Depression
Anxiety
Glucose
Sex Education
Brain
Population
Linear Models
Consensus
Cross-Sectional Studies
Biomarkers
Logistic Models
Regression Analysis
Confidence Intervals
Research
Surveys and Questionnaires

Keywords

  • Agitation
  • Alzheimer's disease
  • Anxiety
  • Apathy
  • Cognitively normal persons
  • Depression
  • FDG-PET
  • Neuroimaging
  • Neuropsychiatric symptoms

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons : The Mayo Clinic Study of Aging. / Krell-Roesch, Janina; Ruider, Hanna; Lowe, Val; Stokin, Gorazd B.; Pink, Anna; Roberts, Rosebud O; Mielke, Michelle M; Knopman, David S; Christianson, Teresa J.; Machulda, Mary Margaret; Jack, Clifford R Jr.; Petersen, Ronald Carl; Geda, Yonas Endale.

In: Journal of Alzheimer's Disease, Vol. 53, No. 4, 2016, p. 1609-1616.

Research output: Contribution to journalArticle

@article{9f39465b0aaa4d70a19b6a19cce0f8c7,
title = "FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging",
abstract = "One of the key research agenda of the field of aging is investigation of presymptomatic Alzheimer's disease (AD). Furthermore, abnormalities in brain glucose metabolism (as measured by FDG-PET) have been reported among cognitively normal elderly persons. However, little is known about the association of FDG-PET abnormalities with neuropsychiatric symptoms (NPS) in a population-based setting. Thus, we conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging in order to examine the association between brain glucose metabolism and NPS among cognitively normal (CN) persons aged>70 years. Participants underwent FDG-PET and completed the Neuropsychiatric Inventory Questionnaire (NPI-Q), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Cognitive classification was made by an expert consensus panel. We conducted multivariable logistic regression analyses to compute odds ratios (OR) and 95 confidence intervals after adjusting for age, sex, and education. For continuous variables, we used linear regression and Spearman rank-order correlations. Of 668 CN participants (median 78.1 years, 55.4 males), 205 had an abnormal FDG-PET (i.e., standardized uptake value ratio<1.32 in AD-related regions). Abnormal FDG-PET was associated with depression as measured by NPI-Q (OR=2.12; 1.233.64); the point estimate was further elevated for APOE ϵ4 carriers (OR=2.59; 1.006.69), though marginally significant. Additionally, we observed a significant association between abnormal FDG-PET and depressive and anxiety symptoms when treated as continuous measures. These findings indicate that NPS, even in community-based samples, can be an important additional tool to the biomarker-based investigation of presymptomatic AD.",
keywords = "Agitation, Alzheimer's disease, Anxiety, Apathy, Cognitively normal persons, Depression, FDG-PET, Neuroimaging, Neuropsychiatric symptoms",
author = "Janina Krell-Roesch and Hanna Ruider and Val Lowe and Stokin, {Gorazd B.} and Anna Pink and Roberts, {Rosebud O} and Mielke, {Michelle M} and Knopman, {David S} and Christianson, {Teresa J.} and Machulda, {Mary Margaret} and Jack, {Clifford R Jr.} and Petersen, {Ronald Carl} and Geda, {Yonas Endale}",
year = "2016",
doi = "10.3233/JAD-160326",
language = "English (US)",
volume = "53",
pages = "1609--1616",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons

T2 - The Mayo Clinic Study of Aging

AU - Krell-Roesch, Janina

AU - Ruider, Hanna

AU - Lowe, Val

AU - Stokin, Gorazd B.

AU - Pink, Anna

AU - Roberts, Rosebud O

AU - Mielke, Michelle M

AU - Knopman, David S

AU - Christianson, Teresa J.

AU - Machulda, Mary Margaret

AU - Jack, Clifford R Jr.

AU - Petersen, Ronald Carl

AU - Geda, Yonas Endale

PY - 2016

Y1 - 2016

N2 - One of the key research agenda of the field of aging is investigation of presymptomatic Alzheimer's disease (AD). Furthermore, abnormalities in brain glucose metabolism (as measured by FDG-PET) have been reported among cognitively normal elderly persons. However, little is known about the association of FDG-PET abnormalities with neuropsychiatric symptoms (NPS) in a population-based setting. Thus, we conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging in order to examine the association between brain glucose metabolism and NPS among cognitively normal (CN) persons aged>70 years. Participants underwent FDG-PET and completed the Neuropsychiatric Inventory Questionnaire (NPI-Q), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Cognitive classification was made by an expert consensus panel. We conducted multivariable logistic regression analyses to compute odds ratios (OR) and 95 confidence intervals after adjusting for age, sex, and education. For continuous variables, we used linear regression and Spearman rank-order correlations. Of 668 CN participants (median 78.1 years, 55.4 males), 205 had an abnormal FDG-PET (i.e., standardized uptake value ratio<1.32 in AD-related regions). Abnormal FDG-PET was associated with depression as measured by NPI-Q (OR=2.12; 1.233.64); the point estimate was further elevated for APOE ϵ4 carriers (OR=2.59; 1.006.69), though marginally significant. Additionally, we observed a significant association between abnormal FDG-PET and depressive and anxiety symptoms when treated as continuous measures. These findings indicate that NPS, even in community-based samples, can be an important additional tool to the biomarker-based investigation of presymptomatic AD.

AB - One of the key research agenda of the field of aging is investigation of presymptomatic Alzheimer's disease (AD). Furthermore, abnormalities in brain glucose metabolism (as measured by FDG-PET) have been reported among cognitively normal elderly persons. However, little is known about the association of FDG-PET abnormalities with neuropsychiatric symptoms (NPS) in a population-based setting. Thus, we conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging in order to examine the association between brain glucose metabolism and NPS among cognitively normal (CN) persons aged>70 years. Participants underwent FDG-PET and completed the Neuropsychiatric Inventory Questionnaire (NPI-Q), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Cognitive classification was made by an expert consensus panel. We conducted multivariable logistic regression analyses to compute odds ratios (OR) and 95 confidence intervals after adjusting for age, sex, and education. For continuous variables, we used linear regression and Spearman rank-order correlations. Of 668 CN participants (median 78.1 years, 55.4 males), 205 had an abnormal FDG-PET (i.e., standardized uptake value ratio<1.32 in AD-related regions). Abnormal FDG-PET was associated with depression as measured by NPI-Q (OR=2.12; 1.233.64); the point estimate was further elevated for APOE ϵ4 carriers (OR=2.59; 1.006.69), though marginally significant. Additionally, we observed a significant association between abnormal FDG-PET and depressive and anxiety symptoms when treated as continuous measures. These findings indicate that NPS, even in community-based samples, can be an important additional tool to the biomarker-based investigation of presymptomatic AD.

KW - Agitation

KW - Alzheimer's disease

KW - Anxiety

KW - Apathy

KW - Cognitively normal persons

KW - Depression

KW - FDG-PET

KW - Neuroimaging

KW - Neuropsychiatric symptoms

UR - http://www.scopus.com/inward/record.url?scp=84981713240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981713240&partnerID=8YFLogxK

U2 - 10.3233/JAD-160326

DO - 10.3233/JAD-160326

M3 - Article

C2 - 27447426

AN - SCOPUS:84981713240

VL - 53

SP - 1609

EP - 1616

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -